BICO Group AB Class B (CLLKF) Stock Price & Analysis
CLLKF Stock Chart & Stats
- Day’s Range
- $2.54 - $2.54
- 52-Week Range
- $1.38 - $2.74
- Previous Close
- $2.47
- Volume
- 500
- Average Volume (3M)
- 222
- Market Cap
- $175.61M
- Enterprise Value
- $1.20B
- Total Cash (Recent Filing)
- $627.60M
- Total Debt (Recent Filing)
- $266.40M
- Price to Earnings (P/E)
- ―
- Beta
- 0.39
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- 0.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Margin Expansion
The sharp improvement in gross margin and adjusted EBITDA margin indicates stronger unit economics and better operating discipline. If sustained, this progress can improve earnings quality, support reinvestment in product development, and strengthen the company’s path toward durable profitability.
Stronger Balance Sheet
The move to net cash materially improves financial flexibility and reduces balance-sheet pressure while the business works through ongoing losses. Greater liquidity can support organic investment, selective bolt-on opportunities, and resilience during periods of uneven project revenue or demand.
Recurring Commercial Opportunity
A 10-year supply and license agreement provides meaningful contracted revenue visibility beyond the current quarter. It also demonstrates the ability to commercialize technology through longer-duration customer relationships, potentially supporting a more durable revenue base alongside instruments and consumables.
Bears Say
Persistent Unprofitability
Deeply negative profitability shows that revenue growth and gross-margin improvement have not yet translated into sustainable earnings. Continued losses can consume financial resources, constrain reinvestment, and increase the risk that future growth requires additional financing or dilution.
Weak Cash Conversion
Negative free cash flow and a large working-capital outflow indicate limited self-funding capacity despite reported operating improvements. Persistent cash conversion weakness could reduce flexibility, create volatility in liquidity needs, and make execution of the growth strategy more dependent on balance-sheet resources.
Project Execution And Demand Risk
Execution problems in the project business and weaker end-market demand can make revenue recognition uneven and delay conversion of the sales pipeline. Longer sales cycles also reduce forecasting reliability, complicate capacity planning, and may limit the durability of near-term commercial improvements.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
What is BICO Group AB Class B’s market cap?
When is BICO Group AB Class B’s upcoming earnings report date?
How were BICO Group AB Class B’s earnings last quarter?
Is BICO Group AB Class B overvalued?
Does BICO Group AB Class B pay dividends?
What is BICO Group AB Class B’s EPS estimate?
How many shares outstanding does BICO Group AB Class B have?
What happened to BICO Group AB Class B’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BICO Group AB Class B?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Anders Fogelberg
- Employees
- 554
- Website
- www.bico.com
- Address
- Grafiska vägen 2B, Gothenburg, VG, 412 63, SE
BICO Group AB Class B (CLLKF) Earnings & Revenues
CLLKF Company Deck
CLLKF Earnings Call
Earnings Call SentimentNeutral
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.
View all CLLKF earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 17 | 4 | 1 |
| Technical Analysis | 5 | 4 | 1 |
| Moving Averages | 12 | 0 | 0 |






